Xaracoll
Product Images NDC 51715-100

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Xaracoll (NDC 51715-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Innocoll Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pouch (Image0001v1)

Pouch (Image0001v1)
This is a description of a pharmaceutical product called "xaraccll" which is a bupivacaine HCI implant intended for surgical use only. Each pouch contains 3x100 mg sterile implants with lot and expiration date information. The dosage is provided as 3 implants equivalent to 300mg bupivacaine HCI. The storage conditions are mentioned and a warning is given not to use if the packaging is damaged. The product is distributed by Innocoll Pharmaceuticals Ltd. in Ireland. The text also includes some non-readable characters.*
FDA Label Image

Carton (Image0002v1)

Carton (Image0002v1)
The text appears to be a description of a medication called Xaracoll. This medication is available in a sterile implant form containing 100mg of Bupivacaine HCl per implant, with each pouch containing three implants. The recommended dosage is three implants, equivalent to 300mg of Bupivacaine HCl. The medication is for surgical implantation and is stored at a temperature between 20°C to 25°C. The text also includes dosage instructions and storage guidelines. The medication is distributed by Innocoll Pharmaceuticals Ltd.*
FDA Label Image

Carton (Image0003v1)

Carton (Image0003v1)
This is a product description for Xaracoll, a bupivacaine hydrochloride implant used for pain relief. The implant comes in single-use cartons, with each carton containing one pouch that has three 100 mg sterile implants. The recommended dosage is three implants equivalent to 300 mg of bupivacaine HCl. The product has a storage temperature requirement of 20-25°C and must not be used if the pouch or blister packaging is damaged. The text also includes dosage information, warnings, a reference to the National Drug Code (NDC) 51715-100-10, and instructions for dispensing.*
FDA Label Image

Carton (Image0004v1)

Carton (Image0004v1)
Xaracoll is a surgical implant that contains bupivacaine HCI, used to manage postoperative pain. Each implant contains 100mg of bupivacaine HCI, equivalent to 88.8mg of bupivacaine. The dosage recommended is three implants equivalent to 300mg of bupivacaine HCI. The product comes in 4 single-use cartons, each containing one pouch containing three sterile implants. The pharmacist should dispense it as a single-use carton with one pouch. It is essential not to use it if the pouch or bister packaging is damaged. Xaracoll should be stored at 20°C to 25°C with excursions permitted between 15°C and 30°C (between 59°F and 86°F). Xaracoll is distributed by Innocoll Pharmaceuticals Ltd in Athlone, Ireland.*
FDA Label Image

Structural Formula (Structureformula)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.